Clinical Trial

Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients

Study acronym: EASTERN
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-12-29; most recent amendment 2024-12-25.
Status change: Not Yet Recruiting → Recruiting 2020-06-02
Trial Details
NCT Number NCT04214990
Lead Sponsor National Cancer Center, Korea
Collaborators: Incheon St.Mary's Hospital/The Catholic University, Kosin University Gospel Hospital, Pusan National University Hospital, SMG-SNU Boramae Medical Center, Chonnam National University Hospital, Chung-Ang University Hospital, Chilgok Kyungpook National University, Hallym University Medical Center, Asan Medical Center, Seoul National University Bundang Hospital, Severance Hospital, Samsung Medical Center
Conditions Aspirin, Gastric Cancer
Enrollment 1,700 participants
Start Date 2020-02-15
Primary Completion 2031-03-31 (estimated)
Study Completion 2032-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-27